1. Home
  2. ATNM vs CNF Comparison

ATNM vs CNF Comparison

Compare ATNM & CNF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Actinium Pharmaceuticals Inc. (Delaware)

ATNM

Actinium Pharmaceuticals Inc. (Delaware)

HOLD

Current Price

$0.80

Market Cap

31.7M

Sector

Health Care

ML Signal

HOLD

CNF

CNFinance Holdings Limited each representing twenty (20)

HOLD

Current Price

$2.22

Market Cap

34.6M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
ATNM
CNF
Founded
2000
1999
Country
United States
China
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Finance: Consumer Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
31.7M
34.6M
IPO Year
2013
2018

Fundamental Metrics

Financial Performance
Metric
ATNM
CNF
Price
$0.80
$2.22
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
$4.50
N/A
AVG Volume (30 Days)
94.4K
36.2K
Earning Date
05-06-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
14.17
N/A
EPS
N/A
N/A
Revenue
$90,000.00
N/A
Revenue This Year
N/A
$252.34
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
11.11
N/A
52 Week Low
$0.74
$0.37
52 Week High
$1.81
$24.00

Technical Indicators

Market Signals
Indicator
ATNM
CNF
Relative Strength Index (RSI) 33.55 42.91
Support Level N/A $2.12
Resistance Level $1.38 $3.49
Average True Range (ATR) 0.04 0.20
MACD -0.00 0.01
Stochastic Oscillator 28.05 23.16

Price Performance

Historical Comparison
ATNM
CNF

About ATNM Actinium Pharmaceuticals Inc. (Delaware)

Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of targeted radiotherapies using its Antibody Radiation Conjugates (ARCs) platform, which combines monoclonal antibodies with radioisotopes to selectively target and destroy cancer cells. The company's product candidates include Iomab-B, an iodine-131 based radiotherapy for conditioning prior to hematopoietic stem cell transplantation, and Actimab-A, an actinium-225 based radiotherapy in clinical development for acute myeloid leukemia. The company is also advancing additional programs, including Iomab-ACT for cell and gene therapy conditioning and other preclinical candidates targeting solid tumors.

About CNF CNFinance Holdings Limited each representing twenty (20)

CNFinance Holdings Ltd is an equity loan service provider. It focuses on the development of small and micro-enterprises. It generates revenue in the form of interest and financing service fees on loans and interest on deposits with banks. Its primary target borrower segment is MSE owners who own real properties in Tier 1 and Tier 2 cities in China. Geographically, the group generates all of its revenues in the PRC.

Share on Social Networks: